Scynexis (SCYX) Share-based Compensation (2013 - 2026)
Scynexis' (SCYX) quarterly Share-based Compensation came in at $580000.0 in Q1 2026, down 29.18% YoY from $819000.0 in Q1 2025, and down 15.57% on a QoQ basis from $687000.0 in Q4 2025.
Scynexis (SCYX) Share-based Compensation (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has 14 years of Share-based Compensation data on file, last reported at $580000.0 in Q1 2026.
- Quarterly Share-based Compensation fell 29.18% year-over-year to $580000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 million (down 25.21% YoY) and the FY2025 annual result came in at $2.9 million, down 14.76% from the prior year.
- Share-based Compensation eased to $580000.0 in Q1 2026, from $687000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $1.1 million in Q2 2022 to a low of $454000.0 in Q4 2022.
- A 5-year average of $752882.4 and a median of $705000.0 in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 125.0% — and 2025, when it plunged 44.44%.
- Tracing SCYX's Share-based Compensation over 5 years: stood at $454000.0 in 2022, then grew by 22.69% to $557000.0 in 2023, then soared by 76.12% to $981000.0 in 2024, then dropped by 29.97% to $687000.0 in 2025, then dropped by 15.57% to $580000.0 in 2026.
- The last three Share-based Compensation figures came in at $580000.0 (Q1 2026), $687000.0 (Q4 2025), and $500000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Scynexis | 62.02 Mn | -52.68 Mn | - | 600,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 600,000.00 |
| Jun 30, 2026 | 600,000.00 |
| Mar 31, 2026 | 580,000.00 |
| Mar 31, 2026 | 580,000.00 |
| Dec 31, 2025 | 687,000.00 |
| Dec 31, 2025 | 687,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Sep 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 820,000.00 |
| Jun 30, 2025 | 820,000.00 |
| Mar 31, 2025 | 819,000.00 |
| Mar 31, 2025 | 819,000.00 |
| Dec 31, 2024 | 981,000.00 |
| Dec 31, 2024 | 981,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 759,000.00 |
| Jun 30, 2024 | 759,000.00 |
| Mar 31, 2024 | 705,000.00 |
| Mar 31, 2024 | 705,000.00 |